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Abstract
Over the last few years, treatment of severe symptomatic aortic stenosis in
high-risk patients has drastically changed to adopt a less-invasive approach.
Transcatheter aortic valve implantation (TAVI) has been developed as a very
reproducible and safe procedure, as shown in many trials. When compared to
surgery, TAVI has produced superior, or at least comparable, results, and thus
a trend to broaden treatment indications to lower-risk patients has erupted as a
natural consequence, even though there is a lack of long-term evidence. In this
review, we summarize and underline aspects that still remain unanswered that
are compulsory if we want to enhance our understanding of this disease.
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Introduction and historical background
Aortic stenosis (AS) is the most common heart valve disease 
worldwide, ranging from 2–4% in patients older than 75 years 
of age1,2. Progressive valve calcification as a degenerative and 
aging process has been found to be the most frequent cause in 
first world countries, followed by congenital alterations (such as 
bicuspid leaflets) and rheumatic disease1. As a result of this 
progressive calcific degeneration, symptoms might remain hidden 
in a latent asymptomatic stage of the disease until signs of left 
ventricular (LV) impairment appear. These include exertional 
dyspnea (shortness of breath), angina-like symptoms (chest pain), 
dizziness, and syncopes and rhythm alterations up to sudden 
death. The latter are unlikely to be found, whereas shortness 
of breath and angina-like symptoms are very common among 
symptomatic patients. The natural history of this pathology, 
being a degenerative and progressive disease, is unstoppable, and 
sooner or later a valve replacement is mandatory in order to 
prevent irreversible hemodynamic changes. Many studies have 
shown advantages of valve replacement over medical treatment2–4.
In order to prevent irreversible changes, such as LV remodeling, 
an invasive treatment is mandatory. In the past, many patients 
were not referred for surgery because of high surgical risk, 
mainly owing to advanced age, LV impairment, and concomitant 
comorbidities4. Thus, a lot of patients were managed con-
servatively. In order to fill this gap comprising almost 33% of 
patients4, a less-invasive alternative treatment was developed. 
The transcatheter aortic valve implantation (TAVI) procedure 
was first described in 20025. Fifteen years later, the TAVI 
procedure has become standard treatment for selected patients. 
Over the last few years, with enhanced diagnostic techniques, 
our understanding of this pathology has changed considerably. 
Today, we address native aortic valve disease with a multidis-
ciplinary heart team that includes interventional cardiologists, 
cardiac surgeons, anesthesiologists, and echocardiographers to 
give patients an adequate therapy. In addition, even if a previous 
surgically implanted bioprosthesis happens to malfunction, 
TAVI appears to be an optimal solution (TAVI-in-valve) in high 
surgical risk populations.
The more we have learned about the disease, the more questions 
have emerged, which is one of the main topics of this article. 
We will focus on recent and current advances addressing 
AS over the last few years and the way it has changed the 
management of the disease itself. In addition, we will underline 
factors of considerable importance that remain incompletely 
understood and that are compulsory if we want to address this 
disease properly.
Current advances
Diagnostic management
Thanks to the introduction of specialized diagnostic tools, 
we can now have a better understanding of the whole valve’s 
anatomy. Through the standardized use of three-dimensional 
(3D) echocardiographic as well as multi-slice computed tomog-
raphy (MSCT) preprocedural assessment before intervention, a 
rapid and accurate visualization and analysis of the aortic valve 
is possible, facilitating the pre-operative planning of aortic valve 
procedures6.
Almost every big trial was performed without 3D 
echocardiography7,8 and moreover without computed tomography 
(CT) scans and the 3D measurements. In order to assess prepro-
cedural measurements, an electrocardiogram (ECG)-triggered 
CT scan of the heart and the whole aorta, including femoral and 
subclavian arteries, is performed. Not only can aortic annulus 
size be studied using MSCT but also leaflet and annulus calcifi-
cation. The latter can be removed during surgery but, if present, 
might stand in the way of TAVI. Other important characteris-
tics to be taken into account are distances between the annulus 
and the coronary ostia that could differ from standard and could 
result in ostial occlusion after implantation. On the other hand, 
left ventricular outflow tract (LVOT) and proportions of the 
ascending aorta are mandatory to achieve a precise and safe 
implantation. Moreover, the peripheral access site and the 
descending aorta can be evaluated for anomalies such as major 
calcification, stenosis, and other factors that could hinder the 
procedure9. MSCT is now an essential tool in terms of access 
site evaluation, prosthesis sizing, and reducing the paravalvular 
leakage and risk of complications6.
Results
Many trials have already shown efficacy and even better 
outcomes than surgery in selected high surgical risk patients7,8,10,11. 
Since then, many patients have been treated with TAVI and 
similar results were achieved. With the passing of the years and 
since positive results were observed, there has been a trend to 
broaden treatment indications8,12,13. The PARTNER 1 trial 
randomized high-risk and non-operable patients to either TAVI 
or surgical aortic valve replacement (SAVR)7. Results regarding 
survival, stroke, bleeding complications, valve hemodynamics, 
and many more were comparable in both groups. All-cause 
mortality (TAVI versus SAVR) was found in 24.2% and in 26.8% 
at 1 year and in 67.8% and in 62.4% at 5 years, respectively. 
Periprocedural stroke appeared more frequently in the TAVI 
group, but 5-year results demonstrated that this difference 
equalized over time (15.9% versus 14.7%). In terms of valve 
hemodynamics and, more specifically, valve deterioration, there 
was no particular difference between the two groups7.
Intermediate-risk patients were enrolled in new trials (SUR-
TAVI and PARTNER 2) and they were consequently treated with 
the transcatheter approach. Results were not as superior as in 
high-risk patients, but they were comparable to SAVR8,12 (See 
Figure 1 and Figure 2, respectively). The main differences 
between the PARTNER 1 and 2 trials were the inclusion of 
lower-risk patients (mean STS 12% versus 5.8%), new available 
devices (SAPIEN versus SAPIEN XT) with enhanced and 
smoother features, and, above all, advanced operator experience. 
In terms of results, the PARTNER 2 trial showed non-inferiority 
compared to SAVR. All-cause mortality rates were similar with 
12.3% versus 12.9% at 1 year, and 16.7% versus 18% at 2 years 
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Figure 1. SURTAVI Outcomes. (a) Confirmation of the non-inferiority margin for TAVI. (b) Time-to-event for death from any cause or 
disabling stroke. (c) Time-to-death from any cause. (d) Time-to-disabling stroke. From Reardon et al., 201712. Reprinted with permission from 
Massachusetts Medical Society.
in the TAVI and SAVR groups, respectively. Disabling stroke 
appeared at a similar frequency at 1 and 2 years and hemodynam-
ics remained stable also.
According to current European guidelines of treatment, early 
therapy should be performed in all symptomatic severe AS 
(Class IB). The decision of whether to choose TAVI over SAVR 
in patients at increased risk should be assessed by the Heart 
Team (Class IB), taking into account individual character-
istics, comorbidities, and technical aspects (Class IC)14 (see 
Table 1).
Actuarial American guidelines of treatment recommend TAVI 
in severe symptomatic AS patients with a prohibitive surgical 
risk and a predicted post-procedural survival greater than 1 year 
(Class IA). Both SAVR and TAVI are recommended for 
severe symptomatic AS and high surgical risk. The decision to 
perform one or the other depends on patient-specific procedural 
risks and more (Class IA). In patients felt to be at an intermedi-
ate risk for surgery, TAVI appears to be a reasonable alternative 
to SAVR in symptomatic individuals, depending on patient- 
specific characteristics (Class IIA and level of evidence C-LD)15 
(see Table 1).
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Figure 2. PARTNER 2 Trial Outcomes. (a) Time-to-event for death from any cause or disabling stroke in the intention-to-treat population, 
(b) in the as-treated population, (c) in the transfemoral-access group in the intention to treat, (d) and in the as-treated analysis. From Leon 
et al., 20168. Reprinted with permission from Massachusetts Medical Society.
Thyregod et al. reported similar results in low-risk patients com-
pared to SAVR, but no significant superiority could be shown 
regarding the primary outcome of study, namely the composite 
of death from any cause, stroke, or myocardial infarction16. 
PARTNER 3 and UK TAVI are ongoing trials that will reveal 
further information about this topic.
TAVI can be easily performed through different access sites, 
such as transfemoral, transsubclavian, transaortic, transcarotid, or 
transapical. The safest as well as the most adopted and favorite 
access point is transfemoral owing to similar or even better 
results in terms of mortality compared to surgery. On the other 
side, transthoracic implantation was linked to comparable or 
worse results than surgery in terms of outcome8. Blackstone 
and colleagues found, in a propensity match analysis from the 
PARTNER 1 trial, a greater periprocedural morbidity and mor-
tality and also longer hospital length of stay in the transapical 
group than in the matched transfemoral population17.
Hemodynamics are better in those patients in short- and long- 
term follow-up than in surgery; in other words, mean gradients are 
lower and valve areas are bigger after TAVI than after SAVR8,12.
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Table 1. Guidelines of treatment for aortic stenosis (AS).
Recommendation Evidence 
grade
American guidelines  
2017 (AHA/ACC) 
TAVI or SAVR in symptomatic severe AS + high surgical risk IA
TAVI for symptomatic severe AS AND a prohibitive risk for SAVR with a post-
TAVI survival of >12 months
IA
TAVI as a reasonable alternative to SAVR for severe symptomatic AS and an 
intermediate surgical risk 
IIa, B–R
Percutaneous aortic balloon dilation may be considered as a bridge to SAVR or 
TAVI for severe symptomatic AS
IIb, C
A heart team is mandatory for patients in whom TAVI or high surgical risk SAVR 
is an option
IC
European guidelines  
2017 (ESC/EACTS) 
TAVI in symptomatic severe AS patients who are not suitable for SAVR assessed 
by a heart team
IB
TAVI or SAVR in patients at increased risk (STS score or EuroSCORE II ≥4% or 
log EuroSCORE ≥10%) or when other risk factors (i.e. frailty, porcelain aorta, 
sequelae of chest radiation) are present
IB
TAVI only in centers with both cardiac surgery AND cardiology with a structured 
collaboration (Heart Team) 
TAVI or SAVR in severe symptomatic AS based on individual evaluation 
including clinical characteristics, anatomical and technical aspects, and 
cardiac conditions in addition to AS
IC 
 
IC
Abbreviations: AHA/ACC, American College of Cardiology/American Heart Association; EACTS, European Association for Cardio-
Thoracic Surgery; ESC, European Society of Cardiology; SAVR, surgical aortic valve replacement; STS, Society of Thoracic Surgeons; 
TAVI, transcatheter aortic valve implantation.
Furthermore, valve durability has been observed in up to 
5 years of follow-up, but it remains an issue over this timeframe. 
Hence, and until consistent evidence is documented, we need 
to be careful and select suitable patients.
Complications
Probably one of the most important complications after TAVI is 
the occurrence of cerebrovascular events (CVEs), which include 
stroke as well as transient ischemic attack (TIA). These have been 
found, according to actuarial data, in several trials in 0.6–10%, 
and their appearance has been linked with an impaired clinical 
outcome with an increased mortality up to tenfold compared to 
patients without stroke18. The Bern TAVI Registry, the Swiss 
TAVI Registry, and the France TAVI Registry showed similar 
incidence rates (3.6%, 3.3%, and 3.6%, respectively)18. As 
mentioned above, the occurrence of CVEs is related to higher 
mortality rates. Eggebrecht et al. showed in a meta-analysis of 
around 10,000 patients an increased mortality after stroke (>3.5-
fold)19. Similar results could be found in the German TAVI 
Registry with a fivefold increase in the in-hospital mortality 
rate20. Differences between first- and new-generation devices 
have prompted a decrease in CVE appearance. Initial data from 
the CoreValve trial suggested stroke rates at 30 days and 1 year 
in 2.3% and 4.3%, respectively, whereas these rates decreased 
in the SURTAVI study to 1.2% and 2.2%. Similar results were 
found in PARTNER 1 and 2 with diminishing stroke rates from 
5.0% to 3.2% at 30 days and 7.8% to 5.0% at 1 year7,8,12,21,22. 
Even though the appearance of this important complication is 
low, its clinical impact is devastating. In this context, and to 
prevent CVEs, it has been suggested that a predilation prior to 
implantation should be abandoned. Hamm and colleagues did 
not find a reduction of CVEs in a retrospective analysis compar-
ing balloon-expandable prostheses with or without predilation. 
However, procedure and fluoroscopy time and subsequent 
radiation were shorter without predilation23. In a small series 
trial, the investigators were not able to show any difference in 
stroke rate with or without predilation. Nonetheless, they found 
a higher number of ischemic brain lesions analyzed by diffusion- 
weighted magnetic resonance imaging (DW-MRI) after TAVI 
without predilation24. Silent cerebral ischemic lesions with no 
particular short-term neurological deficit are present in around 
70–100% of all TAVI patients, and they have been suggested to be 
linked with poor neurological outcome25,26.
Another method to reduce CVE incidence would be the use of 
embolic protection devices (EPDs) during TAVI. The SENTINEL 
trial studied the use of one of these EPDs. However, even though 
it was a safe procedure, there was no statistical significance in 
major adverse cardiovascular and cerebrovascular events 
(MACCEs) and stroke reduction27. In another trial, the DEFLECT 
III, the authors were able to prove reduction in the primary 
in-hospital safety endpoint (death, stroke, major bleeding, major 
vascular complication, and acute kidney injury) and also free-
dom from new ischemic brain lesions was greater, assessed with 
DW-MRI28. Whether we want to apply EPDs generally must be 
investigated in detail.
Moderate to severe paravalvular aortic regurgitation (AR), 
although a natural consequence, is an unwanted complication 
after TAVI, with an incidence of 12.2% seen in the PARTNER 
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trial; this is contrary to SAVR, where this condition is uncommon 
and has been found in only 0.9%29. Moderate to severe paraval-
vular AR is strongly associated with lower short- and long-term 
survival rates compared to those patients with no to mild paraval-
vular AR after TAVI7,8. It has been proved that the appearance of 
paravalvular leak (PVL) has a relationship with annulus under-
sizing as well as severe annular calcification and incorrect 
implantation of the prosthesis30. Nowadays, the incidence of a 
hemodynamic relevant PVL should be expected to be lower, 
thanks to a much broader spectrum of devices (sizes, models, etc.) 
and thanks to new imaging methods (MSCT analysis)6,31. The 
main differences between first-generation devices with regard to 
relevant PVL must be noted. Adams et al. reported an incidence of 
14.6% at 1 year with the self-expandable valve32, whereas Reardon 
and colleagues found relevant PVL in 5.3% of cases at 1 year12. 
As expected, a reduction between first- and second-generation 
balloon-expandable valves was also found with a 1-year inci-
dence of PVL ≥3+ in 6.8% and 3.4%, respectively. These findings 
can be explained through smoother device design and, of course, 
thanks to enhanced operator experience7,8,12,32.
A couple of techniques have been described to suppress PVL, 
such as balloon post dilatation, valve-in-valve implantation, the 
so-called snare technique, and interventional closure depending 
on PVL pathology30 in addition to surgical correction. Interven-
tional closure has been shown to be a safe and effective alterna-
tive with comparable results to surgical correction in selected 
patients33–35. When taking into account younger trials with novel 
devices, we should be able to observe a decreasing trend of 
relevant PVL appearance.
Major vascular complication originates mainly from the punc-
ture area, namely the groin in transfemoral approaches, and is 
also influenced by antithrombotic/antiplatelet therapy. Through 
the introduction of smaller, less harmful catheters and sheaths, 
the complication rate has decreased substantially31. In addi-
tion, closure devices have been developed to prevent such events 
(i.e. access site bleeding) in order to minimize complications 
and longer hospitalizations.
Pacemaker implantation is required in 5.9 to 25.8% after TAVI, 
due to atrioventricular dissociation, depending on the type of 
the implanted valve. It has been linked to higher hospitaliza-
tion time, re-hospitalization, and higher mortality in short-term 
follow-up36.
Antiplatelet and anticoagulation therapy
Current guidelines regarding antithrombotic therapy after TAVI 
recommend the use of antiplatelet drugs and oral anticoagulants 
depending on the concomitant comorbidities, even though there 
has been no randomized evaluation that has focused on optimal 
strategies37,38. The fact that up to 30% of patients undergoing 
TAVI have an indication for oral anticoagulation stands in the 
way of proper antithrombotic therapy39.
Ongoing trials (ARTE, AUREA, ATLANTIS, and GALILEO) 
will hopefully provide us with more evidence on which agent 
is most suitable. The Aspirin Versus Aspirin + ClopidogRel 
Following Transcatheter Aortic Valve Implantation: the ARTE 
Trial (ARTE) is seeking to compare the use of aspirin and 
clopidogrel as a dual antiplatelet therapy and aspirin alone in 
preventing major ischemic events, like ischemic stroke and 
myocardial infarction or death, without raising the risk of major 
bleeding events at 12 months.
Investigating the incidence of major vascular events (hemor-
rhagic or ischemic) 3 months after TAVI and consequently initia-
tion with antithrombotic treatment with either oral anticoagulation 
or dual antiplatelet therapy is the principal purpose of the Dual 
Antiplatelet Therapy Versus Oral Anticoagulation for a Short 
Time to Prevent Cerebral Embolism After TAVI (AUREA) trial. 
Magnetic resonance imaging (MRI) will be performed 3 months 
post-replacement in both arms to evaluate cerebral changes.
In ATLANTIS (Anti-Thrombotic Strategy to Lower All 
Cardiovascular and Neurologic Ischemic and Hemorrhagic Events 
After Trans-Aortic Valve Implantation for Aortic Stenosis), 
the investigators formulate the hypotheses that apixaban (an 
anti-factor-XA inhibitor) is superior to standard-of-care therapies 
to prevent cardiovascular events after TAVI. Primary outcomes 
comprise death, myocardial infarction, stroke, systemic embolism, 
intracardiac or bioprosthesic thrombus, any episode of deep 
vein thrombosis or pulmonary embolism, and life-threatening, 
disabling, or major bleeding at 1-year follow-up40.
With a similar primary outcome to ATLANTIS, a total of 
around 1,500 patients after successful TAVI and without atrial 
fibrillation will be enrolled in the Global Study Comparing a 
rivAroxaban-based Antithrombotic Strategy to an antipLatelet-
based Strategy After Transcatheter aortIc vaLve rEplacement 
to Optimize Clinical Outcomes (GALILEO) study. An antico-
agulation therapy with aspirin and rivaroxaban will be compared 
to standard-of-care dual antiplatelet-based therapy after TAVI 
for 3 months. Afterwards, monotherapy with either rivaroxaban or 
aspirin will be continued41.
Prosthetic valve thrombosis decreased leaflet motion and 
prosthetic valvular endocarditis
Occurring in less than 1% of cases, symptomatic transcatheter 
aortic-valve thrombosis is a very rare condition that might be 
associated with decreased leaflet motion in its initial stages. 
Several coexisting factors have been theoretically postulated 
to be associated with prosthetic valve thrombosis (PVT): 
(i) prothrombotic factors, (ii) the metallic structure as well as an 
(iii) inadequate expansion of the prosthesis, (iv) an insufficient 
contact to the aortic wall that might delay endothelialization, and 
(v) the reminiscent native leaflets that could create blood flow 
stagnation.
Asymptomatic decreased leaflet motion has been assessed and 
confirmed through 4-dimensional CT scan and transesophageal 
echocardiography (TOE) but not with transthoracic echocar-
diography (TTE). CT scan was felt to be more accurate in 
diagnosing PVT than TEE. Almost 75% of the patients in whom 
PVT was found were successfully treated with any form of 
anticoagulation42–44. Larger trials are mandatory in order to 
confirm risk factors as well as to establish standard PVT 
management.
Page 7 of 11
F1000Research 2018, 7(F1000 Faculty Rev):58 Last updated: 16 JAN 2018
Because of the less-invasive nature of transcatheter valve inter-
ventions, one would be forgiven for thinking that the inci-
dence of prosthetic valve endocarditis (PVE) is lower than in 
surgery. In fact, early PVE tends to appear in between 0.3% 
and 3.4% according to actuarial data, wherein the incidence of 
surgical PVE is around 0.3% and 1.2% per patient year with a 
mortality of >20%44. In the PARTNER trial, surgical and tran-
scatheter PVE were present at a similar rate7. The available 
literature suggests on one hand that PVE is associated with 
risk factors such as diabetes, chronic kidney disease, immuno-
suppression, and recurrent infections43; however, on the other 
hand, male sex, low implantation site, ≥ moderate PVL, valve- 
in-valve, and vascular complications have also been suggested 
to be associated with higher risks of PVE. Periprocedural factors 
could also support endocarditis (i.e. failure on antibiotic proph-
ylaxis and dental procedures, lower cath-lab sterilization 
conditions). Reported cases treated conservatively with antibiot-
ics resulted in acceptable outcomes with an in-hospital mortality 
lower than SAVR (11% and 22%, respectively)44,45.
Structural valve failure
In terms of structural valve failure (SVF) in surgical valves, 
Pibarot et al. reported a rate of failure in patients older than 
70 years of age of <10% at 10 years2. In younger patients 
(<40 years of age), however, the incidence of structural failure is 
around 20–30%. The incidence of SVF with respect to TAVI is 
low with no reported valve deterioration or need to replace at 
5 years in the PARTNER trial7. Smaller trials also suggest simi-
lar failure rates2. Owing to the natural high-risk patient character-
istics and their lower expected survival, a proper evaluation with 
longer-term follow-up similar to surgery is of utter importance 
if we expect to broaden indications to lower-risk patients.
Valve Academic Research Consortium-2 criteria
In 2011, the first edition of The Valve Academic Research 
Consortium (VARC) criteria manuscript was published, aim-
ing to get a consensus in selecting appropriate clinical endpoints 
reflecting not only device- but also patient- and procedure- 
related safety and effectiveness, as well as standardizing 
definitions for single and composite clinical endpoints for 
TAVI in clinical trials. The VARC-2 criteria were described 
subsequently to update definitions and selection of TAVI 
endpoints for actuarial and future trials and to enhance risk 
stratification and case selection46 (see Table 2).
Follow-up assessment, as mentioned above, should document 
valve imaging and changes in morphology, comparing this 
measurements with patients’ own post-implant imaging. An 
Table 2. Valve Academic Research Consortium (VARC)-2 criteria.
Risk stratification STS score and EuroSCORE should include other factors (frailty, porcelain aorta, severe 
liver disease, hostile chest, severe pulmonary hypertension) as well as co-existing 
conditions (i.e. anemia, dementia) 
Immediate procedural mortality Death within 72 hours after TAVI
Myocardial infarction (periprocedural 
<72 hours and spontaneous  
>72 hours)
Systematic collection of biomarkers prior to TAVI, within 12–24 hours after TAVI, at  
24 hours thereafter, and at 72 hours or at discharge. If still elevated, daily until decline 
shows up.
Stroke; TIA Disabling and non-disabling using the modified Rankin scale (mRS)
and detailed stroke etiology Ischemic, hemorrhagic, and undetermined 
Access site Detailed information regarding access site and pre-planned vascular closure technique
Vascular complications Access (i.e. iliac rupture) and non-access site-related (ascending aorta dissection or 
rupture, etc.)
Closure device failure Not anymore within vascular complications; considered as part of the TAVI procedure, 
unless clinical consequences are documented
Bleeding complications As a result of overt bleeding and not only as a result of blood transfusion
Acute kidney injury (AKI) From 72 hours to 7 days according to AKIN guidelines
Assessment of conduction 
disturbances
New and/or worsened conduction disturbances; up to 72 hours’ continuous monitoring 
Echocardiography parameters Valve function: position, morphology, evaluation of left and right ventricle size and 
function; patients’ own initial post-implant measurements should be used as a reference; 
hemodynamics initially: one flow-dependent (i.e. mean gradient) and one flow-
independent (i.e. effective orifice area [EOA]) criterion, if discordance then Doppler 
velocity index (DVI) should be calculated. Indexed EOA should be assessed in other to 
unmask prosthesis-patient-mismatch (PPM).
Follow-up assessments Valve imaging and documentation of changes in morphology
Quality of life (QOL) assessment Heart-failure-specific measure (The Minnesota Living with Heart Failure Questionnaire 
[MLHF] and/or the Kansas City Cardiomyopathy Questionnaire [KCCQ]) and a more 
generic measure between 30 days and 5 years
Composite endpoints Time-related valve safety: a combination of valve dysfunction, endocarditis, and 
thrombotic complications of the prosthesis; valve performance through the indexed EOA
Abbreviations: AKIN, Acute Kidney Injury Network; STS, Society of Thoracic Surgeons; TAVI, transcatheter aortic valve implantation; VARC, Valve 
Academic Research Consortium.
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alteration in hemodynamics, such as a reduction in the Doppler 
velocity index (DVI) >0.1–0.13, a decrease in the effective orifice 
area (EOA) of more than 0.3–0.4 cm², or an increasing mean 
gradient >10 mmHg, suggest a change in valve function.
New devices
Initial studies were performed with first-generation devices, 
which have been enhanced over the last few years. We now have 
a wide variety of different prostheses and sizes that help us make 
the best decision and individual selection. It has been proposed 
that new implantation tools have a potential to reduce compli-
cations (PVL, pacemaker implantation, stroke, and vascular 
complications) at long-term follow-up. The design of these 
prostheses has been reshaped in order to achieve a smoother, 
more precise structure that adapts better to native anatomical 
tissues23.
Conclusion
Many questions still remain unanswered. We know that TAVI is 
a very feasible procedure that, in terms of outcomes in high-risk 
patients, is even better than surgery. Results in intermediate- and 
lower-risk patients are comparable to surgery, but we still need 
more evidence if we want to broaden indications. Complications 
if they appear are manageable; nevertheless, the impact of them, 
in terms of both valve failure and long-term results, still remains 
an issue.
The future belongs to TAVI, indeed, but contrary to surgery, 
where large analyses exist, we do not really know about long- 
term durability, and, above all, we do not know if changes will be 
the same in patients at intermediate or lower risk.
Abbreviations
3D, three-dimensional; AR, aortic regurgitation; AS, aortic 
stenosis; CT, computed tomography; CVE, cerebrovascular 
event; DVI, Doppler velocity index; DW-MRI, diffusion-weighted 
magnetic resonance imaging; ECG, electrocardiogram; EOA, 
effective orifice area; EPD, embolic protection device; LV, left 
ventricular; LVOT, left ventricular outflow tract; MSCT, multi-
slice computed tomography; PVE, prosthetic valve endocarditis; 
PVL, paravalvular leak; PVT, prosthetic valve thrombosis; 
SAVR, surgical aortic valve replacement; SVF, structural valve 
failure; TAVI, transcatheter aortic valve implantation; TIA, 
transient ischemic attack; TOE, transesophageal echocardiog-
raphy; TTE, transthoracic echocardiography; VARC, The Valve 
Academic Research Consortium.
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